Petra Acquisition Inc (PAIC) Peer Comparison
$6.90
$-0.59
(-7.88%)
As on 14-Jan-2022 09:30EDT
Market cap
$55 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1
Div. Yield
0 %
Edit
| Petra Acquisition Inc (PAIC) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
55 | 16,765 | 13,492 | 12,332 | 11,994 |
Revenue ($ Mln) |
-- | 2,782 | 2,436 | 1,284 | 670 |
Net Profit ($ Mln) |
-2.34 | 491.50 | 860.62 | -325.10 | -319.95 |
Net Margin (%) |
-- | 17.67 | 35.33 | -25.32 | -47.79 |
RoE (%) |
-3.39 | 110.09 | 42.98 | -57.72 | -71.14 |
Price to Earnings |
-- | 35.25 | 17.40 | -- | -- |
Price-To-Book |
1.00 | 39.29 | 7.42 | 23.98 | 26.87 |
Income Statement ($ Mln)
| Petra Acquisition Inc (PAIC) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.00 | 925.93 | 987.54 | 0.00 | 87.99 |
|
Cost of Revenue
|
0.00 | 647.20 | 36.27 | 0.47 | -- |
|
Gross Profit
|
-- | 278.73 | 951.27 | -0.47 | 87.99 |
|
Operating Expenses
|
1.96 | 111.68 | 841.21 | 206.67 | 175.21 |
|
Operating Profit (EBIT)
|
-1.96 | 167.04 | 110.06 | -206.67 | -93.16 |
|
Other Income
|
0.00 | 1.18 | 0.91 | 4.33 | -0.58 |
|
Profit before Tax
|
-2.34 | 168.53 | 130.84 | -202.24 | -84.55 |
|
Provision for Tax
|
0.00 | 23.15 | 19.06 | -4.80 | 0.00 |
|
Profit after Tax (Net Income)
|
-2.34 | 145.38 | 111.78 | -197.44 | -84.55 |
|
Minority Interest
|
0.00 | -- | -- | -- | -- |
|
Consolidated Profit
|
-2.53 | 145.38 | 111.78 | -202.24 | -84.55 |
Liabilities ($ Mln)
| Petra Acquisition Inc (PAIC) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
66.91 | 805.78 | 1,879.11 | 239.97 | 461.78 |
|
Minority Interest
|
0.00 | -- | -- | -- | -- |
|
Non-Current Liabilities
|
2.91 | 144.79 | 53.56 | 0.47 | 20.04 |
|
Current Liabilities
|
3.74 | 440.11 | 204.66 | 46.56 | 40.68 |
|
Total Liabilities
|
74.16 | 1,390.68 | 2,137.33 | 287.00 | 522.50 |
Assets ($ Mln)
| Petra Acquisition Inc (PAIC) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
73.52 | 917.03 | 691.94 | 1.83 | 200.13 |
|
Current Assets
|
0.04 | 473.65 | 1,445.40 | 285.16 | 322.37 |
|
Total Assets
|
74.16 | 1,390.68 | 2,137.33 | 287.00 | 522.50 |
|
Total Debt*
|
0.00 | 115.14 | 49.09 | 0.79 | 21.14 |
|
Net Current Assets
|
-3.70 | 33.54 | 1,240.74 | 238.61 | 281.69 |
Cashflow ($ Mln)
| Petra Acquisition Inc (PAIC) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-0.22 | 258.68 | 208.98 | -157.56 | -95.80 |
|
Cash Flow from Investing Activities
|
-74.04 | -31.21 | -131.22 | 159.78 | -240.78 |
|
Cash from Financing Activities
|
74.27 | -82.28 | -25.13 | 5.09 | 257.95 |
|
Net Cash Inflow / Outflow
|
-- | 145.18 | 52.64 | 7.31 | -78.22 |
Ratios
Profitability Ratios
| Petra Acquisition Inc (PAIC) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-0.38 | 17.18 | 6.10 | -60.01 | -23.24 |
|
ROE (%)
|
-3.39 | 18.98 | 6.27 | -60.15 | -23.94 |
|
ROA (%)
|
-5.78 | 11.48 | 5.56 | -54.16 | -19.39 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-- | 15.68 | 11.31 | -4,560.96 | -96.73 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Petra Acquisition Inc (PAIC) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | 0.08 | 0.02 | -- | -0.48 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-- | 44.74 | -65.18 | -171.17 | -224.39 |
|
EPS Growth (%)
|
-- | 0.46 | -0.66 | -1.70 | -2.18 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Petra Acquisition Inc (PAIC) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-- | 36.05 | 57.37 | -8.71 | -52.33 |
|
Price / Book Value
|
-- | 6.50 | 3.41 | 7.17 | 9.58 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
3.74 | 27.22 | 44.09 | -6.97 | -47.36 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Petra Acquisition Inc (PAIC) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.14 | 0.03 | 0.00 | 0.05 |
|
Short term debt to equity ratio
|
0.00 | 0.17 | 0.00 | 0.00 | 0.00 |
|
Current Ratio
|
0.01 | 1.08 | 7.06 | 6.13 | 7.92 |
|
Quick Ratio
|
0.01 | 0.92 | 6.96 | -- | 7.82 |
|
Interest Coverage
|
-- | 544.11 | -- | -47.74 | -0.01 |
Operating Efficiency Ratios
| Petra Acquisition Inc (PAIC) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | 17.38 | 16.29 | -- | 0.96 |
|
Asset Turnover
|
0.00 | 0.73 | 0.49 | 0.00 | 0.20 |
|
Receivable days
|
-- | 62.45 | 51.77 | -- | 3.13 |
|
Inventory Days
|
-- | 0.00 | 170.48 | -- | -- |
|
Payable days
|
-- | 13.81 | 177.29 | 851.09 | -- |
|
Cash Conversion Cycle
|
-- | 48.64 | 44.95 | -- | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
